Are Peptides Legal? FDA Compounding Status Explained (2026)

Short answer: Peptides fall into three regulatory buckets: FDA-approved drugs that can be prescribed normally; substances eligible for pharmacy compounding under sections 503A and 503B; and research-use-only chemicals that may not lawfully be administered to humans. In 2023 the FDA placed BPC-157, ipamorelin, epitalon, and several others into compounding category 2, citing significant safety risks.

The three buckets

Approved drugs — semaglutide, tirzepatide, tesamorelin, bremelanotide and others, prescribed on label or off label by a licensed clinician.
Compoundable substances — permitted under 503A/503B where the substance is on an acceptable list.
Research use only — sold with a label stating it is not for human consumption. Administering it is outside the legal and clinical framework entirely.

What category 2 means

Category 2 substances were reviewed and found to present significant safety risks. Licensed 503A pharmacies may not compound them. A site still selling them to consumers is either operating outside pharmacy regulation or selling research chemicals with a disclaimer.

← Back to peptide therapy: evidence, legality, and safety

Want a straight answer about whether a peptide is right for you? Kindr clinicians will tell you when the evidence supports it — and when it does not.

Start your visit →

Not ready? Ask Dot, our free AI menopause companion.

Frequently asked questions

Is buying research peptides illegal?

Sale for laboratory research is generally permitted. Administering research-use-only product to a person falls outside that framework and carries both legal and clinical risk.

Can my doctor prescribe BPC-157?

It is not FDA-approved and sits in compounding category 2, so a licensed US pharmacy cannot compound it.

Peptide therapy: evidence, legality, and safety

Evidence grading, regulation, safety, sourcing, and clinical use. Start anywhere.

Pillar guide →An honest map of a field full of marketing. Every major peptide class graded on human evidence, regulatory status, and safety — plus a candidacy quiz, an onset timeline, and the questions to ask before anyone injects anything.Peptide evidence grades →Every major peptide class graded A to D on human trial evidence.Legality and FDA status →Compounding categories, research-use-only labelling, and what is actually prescribable.Peptide safety and side effects →IGF-1 risk, sterility and contamination, drug interactions, and who should never use them.Peptides in menopause →What is realistic for midlife women — and what hormone therapy does better.How to source safely →Pharmacy registration, batch testing, cold chain, and the questions to ask.Peptide stacks, honestly assessed →Why combining unproven compounds multiplies uncertainty rather than benefit.

Other Kindr symptom hubs

The brain fog hub →The menopause sleep hub →Menopause weight gain: causes and treatment →The hot flashes hub →

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

BPC-157 — tissue repair peptidePeptide
GLP-1s in menopauseJournal
TB-500 — recovery & repairPeptide
Menopause & weight gainJournal
GHK-Cu — regenerative copper peptidePeptide
SemaglutidePeptide

Sources

Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022.
Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023.
Falutz J et al. Effects of tesamorelin on visceral adipose tissue. J Acquir Immune Defic Syndr 2010.
Kingsberg SA et al. Bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019.
US Food and Drug Administration. Bulk drug substances nominated for use in compounding — 503A and 503B category listings, 2023.
Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — preclinical review. Curr Pharm Des (preclinical evidence only).

Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.